126 related articles for article (PubMed ID: 20714944)
21. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.
Cheng T; Dai X; Zhou DL; Lv Y; Miao LY
Med Oncol; 2015 Jan; 32(1):407. PubMed ID: 25465061
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
BMC Cancer; 2009 Dec; 9():421. PubMed ID: 19958548
[TBL] [Abstract][Full Text] [Related]
23. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.
De Vita F; Orditura M; Galizia G; Romano C; Roscigno A; Lieto E; Catalano G
Chest; 2000 Feb; 117(2):365-73. PubMed ID: 10669676
[TBL] [Abstract][Full Text] [Related]
24. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
26. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer.
Xu C; Li L; Wang W; Zhang Q; Zhang X; Yang R
J Cell Mol Med; 2021 Mar; 25(6):3169-3172. PubMed ID: 33605059
[TBL] [Abstract][Full Text] [Related]
27. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
28. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer.
Song XY; Zhou SJ; Xiao N; Li YS; Zhen DZ; Su CY; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(8):4765-8. PubMed ID: 24083740
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
Wang Q; Li X; Ren S; Cheng N; Zhao M; Zhang Y; Li J; Cai W; Zhao C; Cao W; Zhou C
PLoS One; 2015; 10(4):e0122792. PubMed ID: 25860145
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Significance of Serum miR-22, miR-125b, and miR-15b in Non-Small Cell Lung Cancer Patients.
Shi GL; Zhang XY; Chen Y; Ma S; Bai WQ; Yin YJ
Clin Lab; 2020 Jun; 66(6):. PubMed ID: 32538046
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
33. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
34. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.
Yang D; Zhou J; Zeng T; Yang Z; Wang X; Hu J; Song Y; Chen L; Peer D; Wang X; Bai C
Cancer Lett; 2015 Aug; 365(1):57-67. PubMed ID: 25976768
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
Zhang QL; Xing XZ; Li FY; Xing YJ; Li J
Oncol Res Treat; 2015; 38(10):496-502. PubMed ID: 26451776
[TBL] [Abstract][Full Text] [Related]
36. Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
Naumnik W; Naumnik B; Niewiarowska K; Ossolinska M; Chyczewska E
Exp Oncol; 2012 Dec; 34(4):348-53. PubMed ID: 23302994
[TBL] [Abstract][Full Text] [Related]
37. Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer.
Baykara M; Yaman M; Buyukberber S; Tufan G; Demirci U; Benekli M; Coskun U; Ozet A; Umit Bagriacik E
J BUON; 2013; 18(4):921-7. PubMed ID: 24344018
[TBL] [Abstract][Full Text] [Related]
38. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
39. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
40. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
